Children to get CRISPR treatment for sickle cell disease in trial
U.S. · TECH · SCIENCE
June 16, 20223 min read576 words
Published: June 16, 2022  |  3 min read576 words
Gene-editing trials for treating sickle cell disease and beta thalassaemia are being extended to include children aged under 12 after the therapies proved successful in ongoing trials involving people aged between 12 and 35. The aim is to treat children early enough to prevent th...
Children to get CRISPR treatment for sickle cell disease in trial Read more

Scores for this article.

Percentage of critic and public trust in this article.
Great Context3
img-contested
N/A
critic score
critic reviews: 0
img-trusted
100%
public score
public reviews: 3
img-contested
N/A
critic score
1 reviews
img-trusted
67%
public score
6 reviews
img-contested
N/A
critic score
0 reviews
img-contested
N/A
public score
3 reviews

CRITIC REVIEWS

There don't seem to be any reviews yet.

PUBLIC REVIEWS

Great Context
Jun 16
I think this is well sourced and the context allows the reader to take the win and still understand what needs to be pushed and aided in order for this win to actually help more people. A little information on how the new science works, but more information on why the treatment is so expensive.
Jun 16
Is this helpful?
Great Context
Jun 16
Fantastic reporting that does an excellent job of explaining in simple language the current state of the technology and its application in early trials for treating beta thalassaemia and sickle cell disease. Great read.
Jun 16
Is this helpful?
Great Context
7 days ago
It is nice to read a story and see successful results that might improve the lives of people with painful, debilitating diseases. When I was young, an old neighbor with Sickle Cell Anemia asked me, "Do you know why they call it sick as hell anemia? Because it makes you sick as hell." To think that pain like what she described could be remedied is happy news. The content includes potential side effects that might be difficult to live with as well as the high expense that might hinder access.
7 days ago
Is this helpful?